Glioma Therapeutics Pipeline Analysis, 2017 - Designation, Collaboration, and Other Developments

The pipeline for glioma therapeutics is expected to experience rising research activities in future due to raise in funding by the orphan disease organization such as, National Organization of Rare Disorders. Many novel therapies such as, gene therapies, cell therapies are being developed for the treatment of glioma. Various technological advancements in research and development techniques is also be one of the key factors leading to the upsurge in the growth of glioma pipeline therapeutics. Additionally, increasing awareness among people regarding various health issues and treatments available is also adding to the development of glioma therapeutic pipeline.

Explore Report at: www.psmarketresearch.com/market-analysis/glioma-therapeutics-pipeline-analysis

Glioma is a type of brain tumour that arise from glial cells, which provide a protective aid to the neuron in brain. There are basically three types of tumours in which glial cells are involved such as, astrocytoma, ependymomas and oligodendromas. Some of the most common symptoms that occur in glioma are, nausea, headache, confusion, memory loss, seizure, one-sided weakness, difficulty in walking and personality changes. Patients already suffering from brain tumour are usually at a high risk of also developing other diseases such as deep vein thrombosis, pulmonary embolism or brain stroke. Glioma in brain can be diagnosed with the help of MRI scanning. The treatments of glioma include, surgery, chemotherapy, brachytherapy, radiation therapy and treatments with steroids.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/glioma-therapeutics-pipeline-analysis/toc-sample

In October 2015, Merck & Co., Inc. and DNAtrix entered into a collaboration for the purpose of developing as well as monitoring the safety and efficacy of the drug DNX-2401, which mostly target the retinoblastoma (Rb) pathway. DNX-2401 has shown strong killing potential against recurrent glioblastoma by inhibiting Retinoblastoma (Rb) pathway, which is usually present in many cancers. In January 2015, Bristol-Myers Squibb and Eli Lilly and Co. entered into a collaboration to evaluate nivolumab in combination with galunisertib in advance solid tumours. Opdivo is a programmed cell death blocker and galunisertib selectively blocks TGF beta signalling pathway, which led to suppression of tumour cell growth.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the companies having a pipeline of glioma therapeutics include, Teva Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., and F. Hoffmann-Le Roche AG, Agios Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Co., Ltd., Angiochem Inc., Eurofarma Laboratorios S.A., Genentech, Inc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.